Nasus Pharma Ltd. Financials
This page shows Nasus Pharma Ltd. (NSRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Nasus Pharma Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nasus Pharma Ltd. carries a low D/E ratio of 0.81, meaning only $0.81 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Nasus Pharma Ltd.'s current ratio of 2.24 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.
Nasus Pharma Ltd. generates a -211.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Nasus Pharma Ltd. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Nasus Pharma Ltd. generates $0.84 in operating cash flow (-$4.9M OCF vs -$5.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Nasus Pharma Ltd. earns $-62.9 in operating income for every $1 of interest expense (-$4.9M vs $78K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Nasus Pharma Ltd. reported -$5.9M in net income in fiscal year 2025. This represents a decrease of 282.2% from the prior year.
Nasus Pharma Ltd. earned $-0.72 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 227.3% from the prior year.
Cash & Balance Sheet
Nasus Pharma Ltd. generated -$4.9M in free cash flow in fiscal year 2025, representing cash available after capex.
Nasus Pharma Ltd. held $1.2M in cash against $0 in long-term debt as of fiscal year 2025.
Nasus Pharma Ltd. had 9M shares outstanding in fiscal year 2025. This represents an increase of 22.4% from the prior year.
Margins & Returns
Nasus Pharma Ltd.'s ROE was -211.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Nasus Pharma Ltd. invested $2.2M in research and development in fiscal year 2025. This represents an increase of 567.8% from the prior year.
Nasus Pharma Ltd. invested $14K in capex in fiscal year 2025, funding long-term assets and infrastructure.
NSRX Income Statement
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
NSRX Balance Sheet
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Total Assets | $5.0M+683.1% | $639K-10.9% | $717K |
| Current Assets | $4.9M+1568.4% | $291K-36.3% | $457K |
| Cash & Equivalents | $1.2M+509.4% | $203K-28.5% | $284K |
| Inventory | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $2.2M-54.9% | $5.0M+26.1% | $3.9M |
| Current Liabilities | $2.2M-56.3% | $5.0M+26.1% | $3.9M |
| Long-Term Debt | N/A | N/A | N/A |
| Total Equity | $2.8M+164.2% | -$4.3M-34.3% | -$3.2M |
| Retained Earnings | -$18.5M-33.1% | -$13.9M-9.9% | -$12.7M |
NSRX Cash Flow Statement
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
NSRX Financial Ratios
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 2.24+2.2 | 0.06-0.1 | 0.12 |
| Debt-to-Equity | 0.81+2.0 | -1.15+0.1 | -1.22 |
| FCF Margin | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Nasus Pharma Ltd. profitable?
No, Nasus Pharma Ltd. (NSRX) reported a net income of -$5.9M in fiscal year 2025.
What is Nasus Pharma Ltd.'s return on equity (ROE)?
Nasus Pharma Ltd. (NSRX) has a return on equity of -211.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nasus Pharma Ltd.'s free cash flow?
Nasus Pharma Ltd. (NSRX) generated -$4.9M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nasus Pharma Ltd.'s operating cash flow?
Nasus Pharma Ltd. (NSRX) generated -$4.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nasus Pharma Ltd.'s total assets?
Nasus Pharma Ltd. (NSRX) had $5.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nasus Pharma Ltd.'s capital expenditures?
Nasus Pharma Ltd. (NSRX) invested $14K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nasus Pharma Ltd. spend on research and development?
Nasus Pharma Ltd. (NSRX) invested $2.2M in research and development during fiscal year 2025.
What is Nasus Pharma Ltd.'s current ratio?
Nasus Pharma Ltd. (NSRX) had a current ratio of 2.24 as of fiscal year 2025, which is generally considered healthy.
What is Nasus Pharma Ltd.'s debt-to-equity ratio?
Nasus Pharma Ltd. (NSRX) had a debt-to-equity ratio of 0.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nasus Pharma Ltd.'s return on assets (ROA)?
Nasus Pharma Ltd. (NSRX) had a return on assets of -117.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nasus Pharma Ltd.'s cash runway?
Based on fiscal year 2025 data, Nasus Pharma Ltd. (NSRX) had $1.2M in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nasus Pharma Ltd.'s Piotroski F-Score?
Nasus Pharma Ltd. (NSRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nasus Pharma Ltd.'s earnings high quality?
Nasus Pharma Ltd. (NSRX) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nasus Pharma Ltd. cover its interest payments?
Nasus Pharma Ltd. (NSRX) has an interest coverage ratio of -62.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nasus Pharma Ltd.?
Nasus Pharma Ltd. (NSRX) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.